Animal models of diabetic retinopathy: Doors to investigate pathogenesis and potential therapeutics

Journal of Biomedical Science

Volumn 20, Issue 1, 2013, Pages

  Jo, Dong Hyun ^a   Cho, Chang Sik ^a   Kim, Jin Hyoung ^a   Jun, Hyoung Oh ^a   Kim, Jeong Hun ^a  

^a Seoul National University   (South Korea)

Author keywords

Animal model; Diabetic retinopathy; Macular edema; Pathologic angiogenesis; Vascular permeabilit

Indexed keywords

AFLIBERCEPT; ANTIDIABETIC AGENT; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE ACETATE;

BLOOD RETINA BARRIER; CATARACT EXTRACTION; CORTICOSTEROID THERAPY; DBA MOUSE; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DIABETOGENESIS; DISEASE MODEL; DOG; DRUG EFFICACY; EXPERIMENTAL ANIMAL; GLYCEMIC CONTROL; GOTO KAKIZAKI RAT; HAPLORHINI; HUMAN; HYPERGLYCEMIA; LASER COAGULATION; NONHUMAN; NONOBESE DIABETIC MOUSE; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PRIORITY JOURNAL; PSEUDOPHAKIA; RETINA; RETINA NEOVASCULARIZATION; REVIEW; RODENT; SPECIES DIFFERENCE; VISUAL IMPAIRMENT; VITRECTOMY; ZEBRA FISH; ZUCKER DIABETIC FATTY RAT; ANIMAL; PATHOLOGY;

ANIMALIA; DANIO RERIO;

ANIMALS; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; HUMANS;

EID: 84879121536     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-20-38     Document Type: Review

References (89)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993 329 14 977 986 8366922
2. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. White NH, Sun W, Cleary PA, Danis RP, Davis MD, Hainsworth DP, Hubbard LD, Lachin JM, Nathan DM, Arch Ophthalmol 2008 126 12 1707 1715 19064853
3. Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology 1991 98 Suppl 5 741 756 2062510
4. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M, Dills D, Kampik A, Pararajasegaram R, Verdaguer JT, Global Diabetic Retinopathy Project Group, Ophthalmology 2003 9 1677 1682 (Pubitemid 37025422)
5. Disappearance and formation rates of microaneurysms in early diabetic retinopathy. Hellstedt T, Immonen I, Br J Ophthalmol 1996 80 2 135 139 10.1136/bjo.80.2.135 8814743 (Pubitemid 26058546)
6. Update on animal models of diabetic retinopathy: from molecular approaches to mice and higher mammals. Robinson R, Barathi VA, Chaurasia SS, Wong TY, Kern TS, Dis Model Mech 2012 5 4 444 456 10.1242/dmm.009597 22730475
7. The Wisconsin Epidemiologic Study of diabetic retinopathy. XIV. Ten-year incidence and progression of diabetic retinopathy. Klein R, Klein BE, Moss SE, Cruickshanks KJ, Arch Ophthalmol 1994 112 9 1217 1228 10.1001/archopht.1994. 01090210105023 7619101 (Pubitemid 24360961)
8. Global prevalence and major risk factors of diabetic retinopathy. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, Chen SJ, Dekker JM, Fletcher A, Grauslund J, Haffner S, Hamman RF, Ikram MK, Kayama T, Klein BE, Klein R, Krishnaiah S, Mayurasakorn K, O'Hare JP, Orchard TJ, Porta M, Rema M, Roy MS, Sharma T, Shaw J, Taylor H, Tielsch JM, Varma R, Wang JJ, Wang N, et al. Diabetes Care 2012 35 3 556 564 10.2337/dc11-1909 22301125
9. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group, Arch Ophthalmol 1985 103 12 1796 1806 2866759
10. Blood-neural barrier: intercellular communication at glio-vascular interface. Kim JH, Kim JH, Park JA, Lee SW, Kim WJ, Yu YS, Kim KW, J Biochem Mol Biol 2006 39 4 339 345 10.5483/BMBRep.2006.39.4.339 16889675
11. Diabetic retinopathy. Antonetti DA, Klein R, Gardner TW, N Engl J Med 2012 366 13 1227 1239 10.1056/NEJMra1005073 22455417
12. How to overcome diabetic retinopathy: focusing on blood-retinal barrier. Jo DH, Kim JH, Kim JH, Immunol Endocr Metab Agents Med Chem 2012 12 2 110 117 10.2174/187152212800389012
13. How to overcome retinal neuropathy: the fight against angiogenesis-related blindness. Jo DH, Kim JH, Kim JH, Arch Pharm Res 2010 33 10 1557 1565 10.1007/s12272-010-1007-6 21052933
14. Human apolipoprotein(a) kringle V inhibits ischemia-induced retinal neovascularization via suppression of fibronectin-mediated angiogenesis. Lim Y, Jo DH, Kim JH, Ahn JH, Hwang YK, Kang DK, Chang SI, Yu YS, Yoon Y, Kim JH, Diabetes 2012 61 6 1599 1608 10.2337/db11-1541 22427380
15. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Jain RK, Science 2005 307 5706 58 62 10.1126/science.1104819 15637262 (Pubitemid 40093472)
16. TGF beta in fibroproliferative diseases in the eye. Saika S, Yamanaka O, Okada Y, Tanaka S, Miyamoto T, Sumioka T, Kitano A, Shirai K, Ikeda K, Front Biosci 2009 1 376 390
17. Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group, Int Ophthalmol Clin 1987 27 4 239 253 2447027
18. Early photocoagulation in patients with either type I or type II diabetes. Ferris F, Trans Am Ophthalmol Soc 1996 94 505 537 8981711 (Pubitemid 26406045)
19. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, Hartnett E, Ip MS, Kim JE, Kollman C, Diabetic Retinopathy Clinical Research Network (DRCR.net), Arch Ophthalmol 2009 127 3 245 251 19273785
20. Pars plana vitrectomy with and without peeling of the inner limiting membrane for diabetic macular edema. Patel JI, Hykin PG, Schadt M, Luong V, Fitzke F, Gregor ZJ, Retina 2006 26 1 5 13 10.1097/00006982-200601000-00002 16395132 (Pubitemid 44391745)
21. Surgical management of the late complications of proliferative diabetic retinopathy. Newman DK, Eye 2010 24 3 441 449 10.1038/eye.2009.325 20139916
22. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, Rubio RG, Ehrlich JS, RISE and RIDE Research Group, Ophthalmology 2012 119 4 789 801 10.1016/j.ophtha.2011.12.039 22330964
23. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Sultan MB, Zhou D, Loftus J, Dombi T, Ice KS, Macugen 1013 Study Group, Ophthalmology 2011 118 6 1107 1118 10.1016/j.ophtha.2011.02.045 21529957
24. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Do DV, Nguyen QD, Boyer D, Schmidt-Erfurth U, Brown DM, Vitti R, Berliner AJ, Gao B, Zeitz O, Ruckert R, Schmelter T, Sandbrink R, Heier JS, DA VINCI Study Group, Ophthalmology 2012 119 8 1658 1665 10.1016/j.ophtha.2012.02.010 22537617
25. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Rajendram R, Fraser-Bell S, Kaines A, Michaelides M, Hamilton RD, Esposti SD, Peto T, Egan C, Bunce C, Leslie RD, Hykin PG, Arch Ophthalmol 2012 130 8 972 979 10.1001/archophthalmol.2012.393 22491395
26. Inhibitory activity of bevacizumab to differentiation of retinoblastoma cells. Heo JW, Kim JH, Cho CS, Jun HO, Kim DH, Yu YS, Kim JH, PLoS One 2012 7 3 33456 10.1371/journal.pone.0033456 22457763
27. Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors. Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, Kurihara T, Darland DC, Young MJ, D'Amore PA, PLoS One 2008 3 11 3554 10.1371/journal.pone.0003554 18978936
28. Targeted deletion of Vegfa in adult mice induces vision loss. Kurihara T, Westenskow PD, Bravo S, Aguilar E, Friedlander M, J Clin Invest 2012 122 11 4213 4217 10.1172/JCI65157 23093773
29. Inhibition of protein kinase C delta attenuates blood-retinal barrier breakdown in diabetic retinopathy. Kim JH, Kim JH, Jun HO, Yu YS, Kim KW, Am J Pathol 2010 176 3 1517 1524 10.2353/ajpath.2010.090398 20110406
30. The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy. Ahn J, Woo SJ, Chung H, Park KH, Ophthalmology 2011 118 11 2218 2226 10.1016/j.ophtha.2011.03. 036 21724263
31. A call for transparent reporting to optimize the predictive value of preclinical research. Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, Crystal RG, Darnell RB, Ferrante RJ, Fillit H, Finkelstein R, Fisher M, Gendelman HE, Golub RM, Goudreau JL, Gross RA, Gubitz AK, Hesterlee SE, Howells DW, Huguenard J, Kelner K, Koroshetz W, Krainc D, Lazic SE, Levine MS, Macleod MR, McCall JM, Moxley RT 3rd, Narasimhan K, Noble LJ, et al. Nature 2012 490 7419 187 191 10.1038/nature11556 23060188
32. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LE, Proc Natl Acad Sci USA 1995 92 23 10457 10461 10.1073/pnas.92.23.10457 7479819
33. Anti-angiogenic effect of caffeic acid on retinal neovascularization. Kim JH, Lee BJ, Kim JH, Yu YS, Kim KW, Vascul Pharmacol 2009 51 4 262 267 10.1016/j.vph.2009.06.010 19589397
34. Enhanced recombinant adeno-associated virus-mediated vascular endothelial growth factor expression in the adult mouse retina: a potential model for diabetic retinopathy. Rakoczy PE, Brankov M, Fonceca A, Zaknich T, Rae BC, Lai CM, Diabetes 2003 52 3 857 863 10.2337/diabetes.52.3.857 12606531 (Pubitemid 36329145)
35. Decursin inhibits VEGF-mediated inner blood-retinal barrier breakdown by suppression of VEGFR-2 activation. Kim JH, Kim JH, Lee YM, Ahn EM, Kim KW, Yu YS, J Cereb Blood Flow Metabol 2009 29 9 1559 1567 10.1038/jcbfm.2009.78
36. Investigation of barrier characteristics in the hyaloid-retinal vessel of zebrafish. Kim JH, Yu YS, Kim KW, Kim JH, J Neurosci Res 2011 89 6 921 928 10.1002/jnr.22607 21412815
37. Zebrafish: a model for understanding diabetic complications. Jörgens K, Hillebrands JL, Hammes HP, Kroll J, Exp Clin Endocrinol Diabetes 2012 120 4 186 187 22402952
38. Induction of hyperglycaemia in zebrafish (Danio rerio) leads to morphological changes in the retina. Gleeson M, Connaughton V, Arneson LS, Acta Diabetol 2007 44 3 157 163 10.1007/s00592-007-0257-3 17721755 (Pubitemid 47313099)
39. Predominant cone photoreceptor dysfunction in a hyperglycaemic model of non-proliferative diabetic retinopathy. Alvarez Y, Chen K, Reynolds AL, Waghorne N, O'Connor JJ, Kennedy BN, Dis Model Mech 2010 3 3-4 236 245 20142328
40. Studies on streptozotocin diabetes. Ganda OP, Rossini AA, Like AA, Diabetes 1976 25 7 595 603 10.2337/diabetes.25.7.595 132382
41. Retinal capillary basement membrane thickness in spiny mice (Acomys cahirinus) with induced and spontaneous diabetes. Beauchemin ML, Leuenberger PM, Babel J, Invest Ophthalmol Vis Sci 1975 14 7 560 562
42. Death of retinal neurons in streptozotocin-induced diabetic mice. Martin PM, Roon P, Van Ells TK, Ganapathy V, Smith SB, Invest Ophthalmol Vis Sci 2004 45 9 3330 3336 10.1167/iovs.04-0247 15326158 (Pubitemid 39121873)
43. Degenerated intramural pericytes ('ghost cells') in the retinal capillaries of diabetic rats. Robison WG Jr, McCaleb ML, Feld LG, Michaelis OE 4th, Laver N, Mercandetti M, Curr Eye Res 1991 10 4 339 350 10.3109/ 02713689108996340 1829996
44. Diabetic retinopathy: morphometric analysis of basement membrane thickening of capillaries in different retinal layers within arterial and venous environments. Anderson HR, Stitt AW, Gardiner TA, Archer DB, Br J Ophthalmol 1995 79 12 1120 1123 10.1136/bjo.79.12.1120 8562548 (Pubitemid 26002688)
45. Loss of cholinergic and dopaminergic amacrine cells in streptozotocin-diabetic rat and Ins2Akita-diabetic mouse retinas. Gastinger MJ, Singh RS, Barber AJ, Invest Ophthalmol Vis Sci 2006 47 7 3143 3150 10.1167/iovs.05-1376 16799061 (Pubitemid 351639794)
46. Limb regeneration is impaired in an adult zebrafish model of diabetes mellitus. Olsen AS, Sarras MP Jr, Intine RV, Wound Repair Regen 2010 18 5 532 542 10.1111/j.1524-475X.2010.00613.x 20840523
47. Oxygen-induced retinopathy in the mouse. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, D'Amore PA, Invest Ophthalmol Vis Sci 1994 35 1 101 111 7507904 (Pubitemid 24046832)
48. Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Connor KM, Krah NM, Dennison RJ, Aderman CM, Chen J, Guerin KI, Sapieha P, Stahl A, Willett KL, Smith LE, Nat Protoc 2009 4 11 1565 1573 10.1038/nprot.2009.187 19816419
49. The range of PaO2 variation determines the severity of oxygen-induced retinopathy in newborn rats. Penn JS, Henry MM, Wall PT, Tolman BL, Invest Ophthalmol Vis Sci 1995 36 10 2063 2070 7657545
50. Clinical and histopathologic features of canine oxygen-induced proliferative retinopathy. McLeod DS, D'Anna SA, Lutty GA, Invest Ophthalmol Vis Sci 1998 39 10 1918 1932 9727415 (Pubitemid 28397274)
51. Hypoxia-induced retinal angiogenesis in zebrafish as a model to study retinopathy. Cao R, Jensen LD, Söll I, Hauptmann G, Cao Y, PLoS One 2008 3 7 2748 10.1371/journal.pone.0002748 18648503
52. Hypoxia-induced retinopathy model in adult zebrafish. Cao Z, Jensen LD, Rouhi P, Hosaka K, Länne T, Steffensen JF, Wahlberg E, Cao Y, Nat Protoc 2010 5 12 1903 1910 10.1038/nprot.2010.149 21127484
53. Protective effect of clusterin on blood-retinal barrier breakdown in diabetic retinopathy. Kim JH, Kim JH, Yu YS, Min BH, Kim KW, Invest Ophthalmol Vis Sci 2010 51 3 1659 1665 10.1167/iovs.09-3615 19875648
54. Anti-glycated albumin therapy ameliorates early retinal microvascular pathology in db/db mice. Clements RS Jr, Robison WG Jr, Cohen MP, J Diabetes Complications 1998 12 1 28 33 10.1016/S1056-8727(97)00051-2 9442812 (Pubitemid 28028759)
55. Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis, and glial reactivation in the retina of db/db mice. Cheung AK, Fung MK, Lo AC, Lam TT, So KF, Chung SS, Chung SK, Diabetes 2005 54 11 3119 3125 10.2337/diabetes.54.11.3119 16249434 (Pubitemid 43334364)
56. Studies on the retina of the diabetic db / db mouse. I. Endothelial cell-pericyte ratio. Midena E, Segato T, Radin S, di Giorgio G, Meneghini F, Piermarocchi S, Belloni AS, Ophthalmic Res 1989 21 2 106 111 10.1159/000266787 2734001 (Pubitemid 19106233)
57. Erythrocyte and leukocyte dynamics in the retinal capillaries of diabetic mice. Tadayoni R, Paques M, Gaudric A, Vicaut E, Exp Eye Res 2003 77 4 497 504 10.1016/S0014-4835(03)00155-6 12957148 (Pubitemid 37040847)
58. Vitreous fluid of db/db mice exhibits alterations in angiogenic and metabolic factors consistent with early diabetic retinopathy. Cohen MP, Hud E, Shea E, Shearman CW, Ophthalmic Res 2008 40 1 5 9 10.1159/000111151 18025835 (Pubitemid 350308296)
59. Inhibition of reactive oxygen species by Lovastatin downregulates vascular endothelial growth factor expression and ameliorates blood-retinal barrier breakdown in db/db mice: role of NADPH oxidase 4. Li J, Wang JJ, Yu Q, Chen K, Mahadev K, Zhang SX, Diabetes 2010 59 6 1528 1538 10.2337/db09-1057 20332345
60. Breeding of a non-obese, diabetic strain of mice. Makino S, Kunimoto K, Muraoka Y, Mizushima Y, Katagiri K, Tochino Y, Jikken Dobutsu 1980 29 1 1 13 6995140 (Pubitemid 10185796)
61. VEGF expression and cell apoptosis in NOD mouse retina. Li CR, Sun SG, Int J Ophthalmol 2010 3 3 224 227 22553559
62. Endothelin antagonism prevents diabetic retinopathy in NOD mice: a potential role of the angiogenic factor adrenomedullin. Shaw SG, Boden JP, Biecker E, Reichen J, Rothen B, Exp Biol Med 2006 231 6 1101 1105 (Pubitemid 43845586)
63. The Ins2Akita mouse as a model of early retinal complications in diabetes. Barber AJ, Antonetti DA, Kern TS, Reiter CE, Soans RS, Krady JK, Levison SW, Gardner TW, Bronson SK, Invest Ophthalmol Vis Sci 2005 46 6 2210 2218 10.1167/iovs.04-1340 15914643
64. Retinal angiogenesis in the Ins2Akita mouse model of diabetic retinopathy. Han Z, Guo J, Conley SM, Naash MI, Invest Ophthalmol Vis Sci 2013 54 1 574 584 10.1167/iovs.12-10959 23221078
65. Microvascular retinopathy in the Zucker diabetic fatty rat. Danis RP, Yang Y, Invest Ophthalmol Vis Sci 1993 34 7 2367 2371 8505219 (Pubitemid 23191268)
66. Acarbose partially inhibits microvascular retinopathy in the Zucker Diabetic Fatty rat (ZDF/Gmi-fa). Yang YS, Danis RP, Peterson RG, Dolan PL, Wu YQ, J Ocul Pharmacol Ther 2000 16 5 471 10.1089/jop.2000.16.471 11110039
67. Diabetes-enhanced tumor necrosis factor-alpha production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy. Behl Y, Krothapalli P, Desta T, DiPiazza A, Roy S, Graves DT, Am J Pathol 2008 172 5 1411 1418 10.2353/ajpath.2008.071070 18403591 (Pubitemid 351671553)
68. Retinal changes in Otsuka long-evans Tokushima Fatty rats (spontaneously diabetic rat)-possibility of a new experimental model for diabetic retinopathy. Lu ZY, Bhutto IA, Amemiya T, Jpn J Ophthalmol 2003 47 1 28 35 10.1016/S0021-5155(02)00631-7 12586175 (Pubitemid 36175532)
69. Retinal capillary changes in Otsuka Long-Evans Tokushima fatty rats (spontaneously diabetic strain). Electron-microscopic study. Miyamura N, Bhutto IA, Amemiya T, Ophthalmic Res 1999 31 5 358 366 10.1159/000055559 10420121 (Pubitemid 29353798)
70. Long-Evans Tokushima fatty (OLETF) rat is not a suitable animal model for the study of angiopathic diabetic retinopathy. Matsuura T, Yamagishi S, Kodama Y, Shibata R, Ueda S, Narama I, Int J Tissue React 2005 27 2 59 62 16035649 (Pubitemid 40975452)
71. Upregulation of retinal vascular endothelial growth factor mRNAs in spontaneously diabetic rats without ophthalmoscopic retinopathy. A possible participation of advanced glycation end products in the development of the early phase of diabetic retinopathy. Segawa Y, Shirao Y, Yamagishi S, Higashide T, Kobayashi M, Katsuno K, Iyobe A, Harada H, Sato F, Miyata H, Asai H, Nishimura A, Takahira M, Souno T, Segawa Y, Maeda K, Shima K, Mizuno A, Yamamoto H, Kawasaki K, Ophthalmic Res 1998 30 6 333 339 10.1159/000055493 9731114 (Pubitemid 28472887)
72. Evaluation of retinal microcirculatory alterations in the Goto-Kakizaki rat. A spontaneous model of non-insulin-dependent diabetes. Miyamoto K, Ogura Y, Nishiwaki H, Matsuda N, Honda Y, Kato S, Ishida H, Seino Y, Invest Ophthalmol Vis Sci 1996 37 5 898 905 8603874
73. Ocular vascular endothelial growth factor levels in diabetic rats are elevated before observable retinal proliferative changes. Sone H, Kawakami Y, Okuda Y, Sekine Y, Honmura S, Matsuo K, Segawa T, Suzuki H, Yamashita K, Diabetologia 1997 40 6 726 730 10.1007/s001250050740 9222654 (Pubitemid 27288120)
74. Antioxidants and an inhibitor of advanced glycation ameliorate death of retinal microvascular cells in diabetic retinopathy. Yatoh S, Mizutani M, Yokoo T, Kozawa T, Sone H, Toyoshima H, Suzuki S, Shimano H, Kawakami Y, Okuda Y, Yamada N, Diabetes Metabol Res Rev 2006 22 1 38 45 10.1002/dmrr.562 (Pubitemid 43154460)
75. Time-dependent course of electroretinograms in the spontaneous diabetic Goto-Kakizaki rat. Matsubara H, Kuze M, Sasoh M, Ma N, Furuta M, Uji Y, Jpn J Ophthalmol 2006 50 3 211 216 10.1007/s10384-005-0315-8 16767374 (Pubitemid 43881994)
76. Vascular architecture of degenerated retina in WBN/Kob rats: corrosion cast and electron microscopic study. Bhutto IA, Miyamura N, Amemiya T, Ophthalmic Res 1999 3 5 367 377 (Pubitemid 29353799)
77. Generation of transgenic mice with mild and severe retinal neovascularisation. Lai CM, Dunlop SA, May LA, Gorbatov M, Brankov M, Shen WY, Binz N, Lai YK, Graham CE, Barry CJ, Constable IJ, Beazley LD, Rakoczy EP, Br J Ophthalmol 2005 89 7 911 916 10.1136/bjo.2004.059089 15965177 (Pubitemid 40904820)
78. In vivo monitoring of VEGF-induced retinal damage in the Kimba mouse model of retinal neovascularization. Ali Rahman IS, Li CR, Lai CM, Rakoczy EP, Curr Eye Res 2011 36 7 654 662 10.3109/02713683.2010.551172 21657827
79. Deguelin inhibits retinal neovascularization by down-regulation of HIF-1alpha in oxygen-induced retinopathy. Kim JH, Kim JH, Yu YS, Shin JY, Lee HY, Kim KW, J Cell Mol Med 2008 12 6A 2407 2415 10.1111/j.1582-4934.2008.00243.x 18208562
80. Characterization of a mouse model of hyperglycemia and retinal neovascularization. Rakoczy EP, Ali Rahman IS, Binz N, Li CR, Vagaja NN, de Pinho M, Lai CM, Am J Pathol 2010 177 5 2659 2670 10.2353/ajpath.2010.090883 20829433
81. A new spontaneously diabetic non-obese Torii rat strain with severe ocular complications. Shinohara M, Masuyama T, Shoda T, Takahashi T, Katsuda Y, Komeda K, Kuroki M, Kakehashi A, Kanazawa Y, Int J Exp Diabetes Res 2000 1 2 89 100 10.1155/EDR.2000.89 11469401
82. Characteristics of diabetic retinopathy in SDT rats. Kakehashi A, Saito Y, Mori K, Sugi N, Ono R, Yamagami H, Shinohara M, Tamemoto H, Ishikawa SE, Kawakami M, Kanazawa Y, Diabetes Metabol Res Rev 2006 22 6 455 461 10.1002/dmrr.638 (Pubitemid 44774049)
83. Electroretinographic study of spontaneously diabetic Torii rats. Okuno T, Oku H, Sugiyama T, Ikeda T, Doc Ophthalmol 2008 117 3 191 196 10.1007/s10633-008-9122-0 18343964
84. Retinal neovascularisation without ischaemia in the spontaneously diabetic Torii rat. Yamada H, Yamada E, Higuchi A, Matsumura M, Diabetologia 2005 478 8 1663 1668 (Pubitemid 41175521)
85. Retinal vessel changes in galactose-fed dogs. Kobayashi T, Kubo E, Takahashi Y, Kasahara T, Yonezawa H, Akagi Y, Arch Ophthalmol 1998 116 6 785 789 10.1001/archopht.116.6.785 9639449 (Pubitemid 28292734)
86. Diabetes like preproliferative retinal changes in galactose-fed dogs. Takahashi Y, Wyman M, Ferris F 3rd, Kador PF, Arch Ophthalmol 1992 110 9 1295 1302 10.1001/archopht.1992.01080210113037 1520120
87. Vasoproliferation in the neonatal dog model of oxygen-induced retinopathy. McLeod DS, Crone SN, Lutty GA, Invest Ophthalmol Vis Sci 1996 37 7 1322 1333 8641835 (Pubitemid 26177308)
88. Ocular structure and function in an aged monkey with spontaneous diabetes mellitus. Johnson MA, Lutty GA, McLeod DS, Otsuji T, Flower RW, Sandagar G, Alexander T, Steidl SM, Hansen BC, Exp Eye Res 2005 80 1 37 42 10.1016/j.exer.2004.08.006 15652524 (Pubitemid 40126512)
89. Retinopathy in monkeys with spontaneous type 2 diabetes. Kim SY, Johnson MA, McLeod DS, Alexander T, Otsuji T, Steidl SM, Hansen BC, Lutty GA, Invest Ophthalmol Vis Sci 2004 45 12 4543 4553 10.1167/iovs.04-0519 15557466 (Pubitemid 39564682) MEST/NRF